These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17513801)

  • 1. Addition of histone deacetylase inhibitors in combination therapy.
    Carraway HE; Gore SD
    J Clin Oncol; 2007 May; 25(15):1955-6. PubMed ID: 17513801
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
    Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
    J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
    Munster P; Marchion D; Bicaku E; Lacevic M; Kim J; Centeno B; Daud A; Neuger A; Minton S; Sullivan D
    Clin Cancer Res; 2009 Apr; 15(7):2488-96. PubMed ID: 19318486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
    Richon VM; O'Brien JP
    Clin Cancer Res; 2002 Mar; 8(3):662-4. PubMed ID: 11895892
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.
    Marchion DC; Bicaku E; Daud AI; Sullivan DM; Munster PN
    Mol Cancer Ther; 2005 Dec; 4(12):1993-2000. PubMed ID: 16373714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes.
    Davies SL; Popert R; Coptcoat M; Hickson ID; Masters JR
    Int J Cancer; 1996 Jan; 65(1):63-6. PubMed ID: 8543398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
    Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
    Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid treatment of glioblastoma multiforme in a child.
    Witt O; Schweigerer L; Driever PH; Wolff J; Pekrun A
    Pediatr Blood Cancer; 2004 Aug; 43(2):181. PubMed ID: 15236290
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical studies of histone deacetylase inhibitors.
    Prince HM; Bishton MJ; Harrison SJ
    Clin Cancer Res; 2009 Jun; 15(12):3958-69. PubMed ID: 19509172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors.
    Kelly WK
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):722-3. PubMed ID: 16163258
    [No Abstract]   [Full Text] [Related]  

  • 11. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
    Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel plus epirubicin in advanced breast cancer.
    Conte PF; Gennari A; Salvadori B; Pazzagli C; Bengala C
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):40-4. PubMed ID: 9516603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin for adjuvant therapy in node-positive breast cancer.
    Med Lett Drugs Ther; 2000 Feb; 42(1071):12-3. PubMed ID: 10725968
    [No Abstract]   [Full Text] [Related]  

  • 15. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
    Hajji N; Wallenborg K; Vlachos P; Füllgrabe J; Hermanson O; Joseph B
    Oncogene; 2010 Apr; 29(15):2192-204. PubMed ID: 20118981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV agents. Valproic acid and HIV eradication--many questions remain.
    TreatmentUpdate; 2005; 17(6):5-7. PubMed ID: 17228476
    [No Abstract]   [Full Text] [Related]  

  • 17. [Valproic acid as a histone deacetylase inhibitor. New application for a well-known drug].
    Wagner JM; Bug G; Jung M
    Pharm Unserer Zeit; 2010 May; 39(3):197-203. PubMed ID: 20425769
    [No Abstract]   [Full Text] [Related]  

  • 18. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
    Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
    Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic therapies reach main street.
    Bates SE
    Clin Cancer Res; 2009 Jun; 15(12):3917. PubMed ID: 19528089
    [No Abstract]   [Full Text] [Related]  

  • 20. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
    Riester D; Hildmann C; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.